Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

NCT06328036 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped Other - Protocol moved to Disapproved

Conditions

Recurrent Glioblastoma, IDH-Wildtype

Interventions

BIOLOGICAL: Atezolizumab
PROCEDURE: Biospecimen Collection
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Surgical Procedure
BIOLOGICAL: Tiragolumab

Sponsor

National Cancer Institute (NCI)